

Effect of Ozanimod (RPC1063) on Action Potential Parameters in Adult Human Purkinje Fibres

Najah Abi-Gerges¹, Paul E. Miller¹, Andre Ghetti¹, Fiona L. Scott², Kristen R. Taylor Meadows², Bryan Clemons², Paul Frohna², Guy Page¹, Gregory J. Opitck²

¹AnaBios Corporation, San Diego, California, United States; ²Receptos, a wholly owned subsidiary of Celgene, San Diego, California, United States

INTRODUCTION AND PURPOSE


- Isolated human Purkinje fibres (PFs) in combination with electrophysiology are a unique tool that can be used to understand subtle differences between drugs on cardiac conduction
- Fingolimod has been associated with second degree or higher atrioventricular (AV) block¹
- Ozanimod has not been shown to be associated with comparable cardiac abnormalities^{2,3}
- Ozanimod (RPC1063) is an oral, once-daily immunomodulator selectively targeting sphingosine-1-phosphate (S1P) receptor subtypes 1 (S1P_{R1}) and 5 (S1P_{R5}) that has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis^{4,5}
- A key difference between fingolimod, a drug used to treat multiple sclerosis, and ozanimod is the former's constitutive signaling through S1P_{R3}
- The hypothesis tested here was to determine the causality of S1P_{R3} agonism on higher-order human cardiac conduction and, therefore, determine whether the higher selectivity of ozanimod explains its improved clinical profile

METHODS

- At pacing rates of 1 and 2 Hz (mimicking normal and elevated heart rates, respectively), human PFs from female hearts were used to evaluate the effects of ozanimod and fingolimod on action potential duration (APD) at 30%, 50%, and 90% repolarization (APD30, APD50, and APD90, respectively) and on recognized pro-arrhythmia predictors (triangulation (APD90-APD30), short-term variability (STV) of APD90, and incidence of early afterdepolarizations (EAD)
- Vehicle control (DMSO 0.3%) and flecainide (10 μ M) were used to determine the stability and responsiveness, respectively, of the PFs⁶

Figure 1. Experimental Design

A) Schematic image of the human heart; B) Isolated PFs; C) PFs in the experimental apparatus; D) PF action potential; E) Experimental design used



RESULTS

Ozanimod showed no significant effects on APD or pro-arrhythmia markers

- Ozanimod, up to a physiological concentration of 150 nM, had no significant effects on APD and did not increase the manifestation of pro-arrhythmia markers or induce beat escape (BE); the electrical stimulus does not trigger an action potential after full repolarization (Figures 1, 2, and 5)

Fingolimod showed effects on pro-arrhythmia markers

- Although fingolimod, up to a physiological concentration of 500 nM, also had no significant effects on APD (Figure 6), triangulation, or EADs, it did elicit an increase in STV (APD90) (Figure 4)
- Moreover, 50 nM fingolimod showed BE, which was more pronounced at 500 nM (Figures 3 and 4)
- Further, PAT-1229, an S1P_{R3} antagonist, was able to reverse fingolimod-induced BE
- Vehicle controls showed no change in APD or any manifestation of pro-arrhythmic markers or BE (data not shown)

RESULTS (continued)

Figure 1. Ozanimod Showed no BE





Figure 2. Ozanimod Pro-Arrhythmia and BE Assessment



The positive control, flecainide, showed changes in APD, triangulation, and BE

- In contrast, flecainide decreased APD30 and APD50, increased triangulation and STV (APD90), with no induction of EADs, but elicited BE (Figures 2 and 4)

Figure 3. BE was Present With Fingolimod




Figure 4. Fingolimod Pro-Arrhythmia and BE Assessment




Figure 5. Ozanimod Showed no Significant Effects on APD





Figure 6. Fingolimod Showed no Significant Effects on APD



CONCLUSIONS

- The model recapitulated the clinical observations that fingolimod treatment causes dose-dependent cardiac conduction abnormalities at concentrations similar to those reported in the peripheral blood and which appear to be the result of S1P_{R3} agonism
- The data agreed with the clinical observation that ozanimod has no effect on the measured conduction parameters, which appear to be the result of ozanimod's higher selectivity
- Future work on cardiac conduction may involve the un-phosphorylated form of fingolimod and the active metabolites of ozanimod and may be extended to the effect of S1P agonists on heart rhythm, through the use of isolated and perfused human sinoatrial node

REFERENCES

- Gilenya® (fingolimod) capsules, for oral use [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.
- Comi G, et al. ECTRIMS 2017 Oral Presentation #232.
- Cohen JA, et al. ECTRIMS 2017 Oral Presentation #280.
- Cohen JA, et al. *Lancet Neurol*. 2016;15:373-81.
- Sandborn WJ, et al. *N Engl J Med*. 2016;374:1754-62.
- Page G, et al. *J Pharmacol Toxicol Methods*. 2016;81:183-95.

ACKNOWLEDGMENTS

We thank Phachareeya Ratchada, Ashley Alamillo, Katrina Sweat, Yannick Miron, and Ky Truong (AnaBios) for technical assistance and Michael G. Baker and colleagues at Samorn Biosciences for medical writing assistance.

DISCLOSURES

N Abi-Gerges, PE Miller, A Ghetti, G Page: Financial support for research, Celgene Corporation.
FL Scott, KR Taylor Meadows, B Clemons, P Frohna, GJ Opitck: Shareholder, Celgene Corporation.



Copies of this poster obtained through the QR Code are for personal use only and may not be reproduced without permission of the author of this poster.